Chronic endothelin blockade in dogs with pacing-induced heart failure: Possible modulation of sympathoexcitation

Patrick I. McConnell, Charles E. Olson, Kaushik P Patel, Douglas U. Blank, Maria Teresa Olivari, Kim P. Gallagher, Edie Quenby-Brown, Irving H Zucker

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide elaborated by many cell types. Plasma ET-1 levels are significantly augmented in patients and experimental animals with heart failure. Enhanced levels of ET-1 may contribute to myocardial depression and alterations in sympathetic nerve activity in the setting of chronic heart failure. The effects of chronic blockade of endothelin A (ET(A)) receptors on the development and severity of experimental heart failure and sympathoexcitation were evaluated in these experiments using the specific ETA antagonist, PD156707. Methods and Results: Four groups of conscious, chronically instrumented mongrel dogs were administered either PD156707 (750 mg orally thrice daily) or a placebo starting 1 day before ventricular pacing or a sham (nonpaced) period. Before pacing or the sham period, baseline hemodynamic and plasma norepinephrine (NE) measurements were made. Hemodynamic and NE measurements were made every 3 to 4 days for the next 28 days. All parameters were relatively stable in nonpaced dogs administered placebo. Paced placebo dogs showed classic hemodynamic and sympathoexcitatory changes indicative of heart failure. Nonpaced dogs administered PD156707 showed a significant decrease in mean arterial pressure and total peripheral resistance beginning 3 days after drug administration. Myocardial function was not affected by PD156707 in nonpaced dogs. In paced dogs, PD156707 also reduced arterial pressure and peripheral resistance. Changes in myocardial function were small and insignificant. Paced dogs administered PD156707 showed an approximately 50% lower increase in plasma NE level from days 10 to 24 compared with paced dogs administered placebo (941.8 ± 122.8 vs 501.1 ± 92.6 pg/mL at 17 days; P < .01). Conclusions: These data suggest that ET- 1 contributes to the maintenance of arterial pressure in both sham dogs and dogs paced into heart failure. ET-1 does not appear to have a potent effect on inotropic state, but the data strongly suggest that ET-1 may contribute to the progressive deterioration of circulatory function in heart failure by mediating sympathoexcitation and enhancing plasma NE concentration.

Original languageEnglish (US)
Pages (from-to)56-65
Number of pages10
JournalJournal of Cardiac Failure
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2000

Fingerprint

Endothelins
Heart Failure
Dogs
Endothelin-1
Norepinephrine
Placebos
Arterial Pressure
Hemodynamics
Vascular Resistance
Endothelin A Receptors
Vasoconstrictor Agents
Maintenance
Peptides

Keywords

  • Contractility
  • ET(A)
  • Norepinephrine
  • Sympathetic nerve activity
  • Ventricular pacing

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Chronic endothelin blockade in dogs with pacing-induced heart failure : Possible modulation of sympathoexcitation. / McConnell, Patrick I.; Olson, Charles E.; Patel, Kaushik P; Blank, Douglas U.; Olivari, Maria Teresa; Gallagher, Kim P.; Quenby-Brown, Edie; Zucker, Irving H.

In: Journal of Cardiac Failure, Vol. 6, No. 1, 01.01.2000, p. 56-65.

Research output: Contribution to journalArticle

McConnell, Patrick I. ; Olson, Charles E. ; Patel, Kaushik P ; Blank, Douglas U. ; Olivari, Maria Teresa ; Gallagher, Kim P. ; Quenby-Brown, Edie ; Zucker, Irving H. / Chronic endothelin blockade in dogs with pacing-induced heart failure : Possible modulation of sympathoexcitation. In: Journal of Cardiac Failure. 2000 ; Vol. 6, No. 1. pp. 56-65.
@article{937ae720f38048668929dbd1f6d92ba8,
title = "Chronic endothelin blockade in dogs with pacing-induced heart failure: Possible modulation of sympathoexcitation",
abstract = "Background: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide elaborated by many cell types. Plasma ET-1 levels are significantly augmented in patients and experimental animals with heart failure. Enhanced levels of ET-1 may contribute to myocardial depression and alterations in sympathetic nerve activity in the setting of chronic heart failure. The effects of chronic blockade of endothelin A (ET(A)) receptors on the development and severity of experimental heart failure and sympathoexcitation were evaluated in these experiments using the specific ETA antagonist, PD156707. Methods and Results: Four groups of conscious, chronically instrumented mongrel dogs were administered either PD156707 (750 mg orally thrice daily) or a placebo starting 1 day before ventricular pacing or a sham (nonpaced) period. Before pacing or the sham period, baseline hemodynamic and plasma norepinephrine (NE) measurements were made. Hemodynamic and NE measurements were made every 3 to 4 days for the next 28 days. All parameters were relatively stable in nonpaced dogs administered placebo. Paced placebo dogs showed classic hemodynamic and sympathoexcitatory changes indicative of heart failure. Nonpaced dogs administered PD156707 showed a significant decrease in mean arterial pressure and total peripheral resistance beginning 3 days after drug administration. Myocardial function was not affected by PD156707 in nonpaced dogs. In paced dogs, PD156707 also reduced arterial pressure and peripheral resistance. Changes in myocardial function were small and insignificant. Paced dogs administered PD156707 showed an approximately 50{\%} lower increase in plasma NE level from days 10 to 24 compared with paced dogs administered placebo (941.8 ± 122.8 vs 501.1 ± 92.6 pg/mL at 17 days; P < .01). Conclusions: These data suggest that ET- 1 contributes to the maintenance of arterial pressure in both sham dogs and dogs paced into heart failure. ET-1 does not appear to have a potent effect on inotropic state, but the data strongly suggest that ET-1 may contribute to the progressive deterioration of circulatory function in heart failure by mediating sympathoexcitation and enhancing plasma NE concentration.",
keywords = "Contractility, ET(A), Norepinephrine, Sympathetic nerve activity, Ventricular pacing",
author = "McConnell, {Patrick I.} and Olson, {Charles E.} and Patel, {Kaushik P} and Blank, {Douglas U.} and Olivari, {Maria Teresa} and Gallagher, {Kim P.} and Edie Quenby-Brown and Zucker, {Irving H}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1071-9164(00)00012-9",
language = "English (US)",
volume = "6",
pages = "56--65",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Chronic endothelin blockade in dogs with pacing-induced heart failure

T2 - Possible modulation of sympathoexcitation

AU - McConnell, Patrick I.

AU - Olson, Charles E.

AU - Patel, Kaushik P

AU - Blank, Douglas U.

AU - Olivari, Maria Teresa

AU - Gallagher, Kim P.

AU - Quenby-Brown, Edie

AU - Zucker, Irving H

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide elaborated by many cell types. Plasma ET-1 levels are significantly augmented in patients and experimental animals with heart failure. Enhanced levels of ET-1 may contribute to myocardial depression and alterations in sympathetic nerve activity in the setting of chronic heart failure. The effects of chronic blockade of endothelin A (ET(A)) receptors on the development and severity of experimental heart failure and sympathoexcitation were evaluated in these experiments using the specific ETA antagonist, PD156707. Methods and Results: Four groups of conscious, chronically instrumented mongrel dogs were administered either PD156707 (750 mg orally thrice daily) or a placebo starting 1 day before ventricular pacing or a sham (nonpaced) period. Before pacing or the sham period, baseline hemodynamic and plasma norepinephrine (NE) measurements were made. Hemodynamic and NE measurements were made every 3 to 4 days for the next 28 days. All parameters were relatively stable in nonpaced dogs administered placebo. Paced placebo dogs showed classic hemodynamic and sympathoexcitatory changes indicative of heart failure. Nonpaced dogs administered PD156707 showed a significant decrease in mean arterial pressure and total peripheral resistance beginning 3 days after drug administration. Myocardial function was not affected by PD156707 in nonpaced dogs. In paced dogs, PD156707 also reduced arterial pressure and peripheral resistance. Changes in myocardial function were small and insignificant. Paced dogs administered PD156707 showed an approximately 50% lower increase in plasma NE level from days 10 to 24 compared with paced dogs administered placebo (941.8 ± 122.8 vs 501.1 ± 92.6 pg/mL at 17 days; P < .01). Conclusions: These data suggest that ET- 1 contributes to the maintenance of arterial pressure in both sham dogs and dogs paced into heart failure. ET-1 does not appear to have a potent effect on inotropic state, but the data strongly suggest that ET-1 may contribute to the progressive deterioration of circulatory function in heart failure by mediating sympathoexcitation and enhancing plasma NE concentration.

AB - Background: Endothelin-1 (ET-1) is a potent vasoconstrictor peptide elaborated by many cell types. Plasma ET-1 levels are significantly augmented in patients and experimental animals with heart failure. Enhanced levels of ET-1 may contribute to myocardial depression and alterations in sympathetic nerve activity in the setting of chronic heart failure. The effects of chronic blockade of endothelin A (ET(A)) receptors on the development and severity of experimental heart failure and sympathoexcitation were evaluated in these experiments using the specific ETA antagonist, PD156707. Methods and Results: Four groups of conscious, chronically instrumented mongrel dogs were administered either PD156707 (750 mg orally thrice daily) or a placebo starting 1 day before ventricular pacing or a sham (nonpaced) period. Before pacing or the sham period, baseline hemodynamic and plasma norepinephrine (NE) measurements were made. Hemodynamic and NE measurements were made every 3 to 4 days for the next 28 days. All parameters were relatively stable in nonpaced dogs administered placebo. Paced placebo dogs showed classic hemodynamic and sympathoexcitatory changes indicative of heart failure. Nonpaced dogs administered PD156707 showed a significant decrease in mean arterial pressure and total peripheral resistance beginning 3 days after drug administration. Myocardial function was not affected by PD156707 in nonpaced dogs. In paced dogs, PD156707 also reduced arterial pressure and peripheral resistance. Changes in myocardial function were small and insignificant. Paced dogs administered PD156707 showed an approximately 50% lower increase in plasma NE level from days 10 to 24 compared with paced dogs administered placebo (941.8 ± 122.8 vs 501.1 ± 92.6 pg/mL at 17 days; P < .01). Conclusions: These data suggest that ET- 1 contributes to the maintenance of arterial pressure in both sham dogs and dogs paced into heart failure. ET-1 does not appear to have a potent effect on inotropic state, but the data strongly suggest that ET-1 may contribute to the progressive deterioration of circulatory function in heart failure by mediating sympathoexcitation and enhancing plasma NE concentration.

KW - Contractility

KW - ET(A)

KW - Norepinephrine

KW - Sympathetic nerve activity

KW - Ventricular pacing

UR - http://www.scopus.com/inward/record.url?scp=0034075903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034075903&partnerID=8YFLogxK

U2 - 10.1016/S1071-9164(00)00012-9

DO - 10.1016/S1071-9164(00)00012-9

M3 - Article

C2 - 10746820

AN - SCOPUS:0034075903

VL - 6

SP - 56

EP - 65

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 1

ER -